Paxlovid™ (nirmatrelvir/ritonavir) – FDA’s Antimicrobial Drugs Advisory Committee recommends Paxlovid
March 16, 2023 - The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) recommended (16 yes and 1 no) that Paxlovid (nirmatrelvir/ritonavir) has a favorable benefit-risk assessment when used for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Top